ArticleBiomedicines2023

Involvement of the AKT Pathway in Resistance to Erlotinib and Cabozantinib in Triple-Negative Breast Cancer Cell Lines.

Cory Lefebvre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.